AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 312 min read$PLUS

Marion Elaine D sold $268K of PLUS (indirect holdings)

Marion Elaine D (CHIEF FINANCIAL OFFICER) sold 2,818 indirectly-held shares of EPLUS INC (PLUS) at an average of $95.22 ($95.22–$95.25, $0.27M total) across 2 trades on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Marion Elaine D
Published Jul 31, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PLUS
Neutral
high confidence
Mentioned
$PLUS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLUSNeutralLow
01

Why it matters

The only new fact is the disclosed sale size, pricing range, and that the CFO ended with 0 shares; there is no accompanying company guidance or event.

02

Market read

Traders may note the CFO’s scheduled selling, but the 10b5-1 framing and lack of other catalysts suggest minimal incremental trading edge.

03

What to watch

Indirect holdings and the CFO’s post-sale position (0 shares) can be mechanically driven by prior grants, taxes, or diversification, reducing signal strength.

Relevance 3/10Novelty 2/10Timing: filed 2026-07-31 after-hours; trades dated 2026-07-29

Background

The article is a SEC Form 4 insider transaction disclosure for EPLUS Inc (PLUS) by its CFO, reported as an indirect holding sale under a 10b5-1 plan.

Company-level read

Ticker impact

$PLUSNeutralHigh confidence
Context

EPLUS CFO Marion Elaine D sold $268,336 of PLUS shares via an open-market sale under a pre-arranged 10b5-1 plan, leaving 0 shares.

Expected impact

Likely limited near-term impact; treat as informational rather than a fundamental reset.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan and no accompanying guidance, deal, or regulatory action.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity without new business information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • public_company
    PLUS

    EPLUS Inc, issuer of the Form 4 insider transaction disclosed in the article.

  • insider
    Marion Elaine D

    Chief Financial Officer of EPLUS Inc, reported as the insider selling shares.

Read at source← All news

Related articles

AUG 5
$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.

financialcontent.com4 min
AUG 4
$PLUSMed

ePlus (NASDAQ:PLUS) Surprises With Q2 CY2026 Sales

ePlus (NASDAQ:PLUS) reported Q2 CY2026 revenue of $649.1 million, up 1.9% year on year, exceeding market expectations. Non-GAAP profit was $1.28 per share, 11.8% above analysts’ consensus. The company cited extended lead times and shipment delays tied to an ongoing memory chip shortage.

financialcontent.com4 min
AUG 4
$PLUSMed

EPLUS INC (PLUS): Results of Operations and Financial Condition

EPLUS INC (PLUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 ef20079242_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ePlus Reports First Quarter Fiscal Year 2027 Financial Results Managed Services Delivers Strong Performance and Increases Recurring Revenue ~ Reiterates Fiscal 2027 Guidance ~ First Quarter of Fiscal Year 2027 ● Net sales

SEC EDGAR 8-K6 min
AUG 4
$PLUSMed

ePlus Reports First Quarter Fiscal Year 2027 Financial Results

ePlus (NASDAQ: PLUS) reported Q1 FY2027 results for the three months ended June 30, 2026. Net sales rose 1.0% to $649.1 million and services revenue rose 2.6% to $119.4 million, while gross profit fell 1.5% to $151.3 million. Net earnings from continuing ops declined 5.4% to $30.3 million and adjusted EBITDA fell 9.2% to $47.8 million. The company reiterated FY2027 mid-single-digit growth guidance and declared a $0.27 quarterly dividend.

prnewswire.com6 min
JUL 13
$PLUSMed

PageGroup & Oxford Nanopore: Markets live

PageGroup shares rose over 11% after it reported Q2 gross profit of £198m, down 0.2% year on year but ahead of analyst expectations, and said it sees signs of market normalisation. ME Group International gained about 11% after interim results showed flat £154m sales. Plus500 shares fell on weaker cash margin, and Oxford Nanopore dropped 12% after H1 sales missed expectations at £116.5m.

investorschronicle.co.uk6 min